Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director comp.
Acq. announced
Appointed director
Notes underwriting agrmnt
|
|
MedTech Acquisition Corp
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/03/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E... |
| 08/16/2023 |
8-K
| Director compensation was amended/approved, Acquisition/merger/asset purchase announced|
Docs:
|
"Second Amended and Restated Certificate of Incorporation of TriSalus Life Sciences, Inc",
"Amended and Restated Bylaws of TriSalus Life Sciences, Inc",
"Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock of TriSalus Life Sciences, Inc",
"Specimen Common Stock Certificate",
"Specimen Warrant Certificate",
"Description of Common Stock",
"April 5, 2023",
"April 5, 2023",
"April 5, 2023",
"April 5, 2023" |
|
| 08/09/2023 |
8-K
| Submission of Matters to a Vote of Security Holders, Other Events Interactive Data |
| 08/02/2023 |
8-K
| Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits Interac... |
| 08/02/2023 |
8-K
| Quarterly results |
| 07/21/2023 |
8-K
| Quarterly results |
| 07/06/2023 |
8-K
| Entered into an underwriting agreement for the issuance and sale of notes|
Docs:
|
"THIRD Amendment To Agreement AND PLAN OF MERGER THIS THIRD AMENDMENT TO AGREEMENT AND PLAN OF MERGER , dated as of July 5, 2023, is made and entered into by and among MedTech Acquisition Corporation, a Delaware corporation , MTAC Merger Sub, Inc., a Delaware corporation and direct, wholly owned subsidiary of Acquiror , and TriSalus Life Sciences, Inc., a Delaware corporation . Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Merger Agreement . RECITALS A. WHEREAS, Acquiror, Merger Sub and the Company are parties to that certain Agreement and Plan of Merger, dated as of November 11, 2022, as amended pursuant to that certain First Amendment to Agreement and Plan of Merger, dated as of April 4, 2023 and Second Amendment to Agreement and P...",
"SUBSCRIPTION AGREEMENT",
"Letter re: Termination of Backstop Letter Agreement" |
|
| 06/30/2023 |
8-K
| Unregistered Sales of Equity Securities Interactive Data |
| 06/12/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 06/08/2023 |
8-K
| Entered into an underwriting agreement for the issuance and sale of notes |
| 05/15/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 04/20/2023 |
8-K
| Quarterly results |
| 04/05/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 03/08/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 12/21/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data|
Docs:
|
"TriSalus Video Transcript Text on screen: Dr. Carvajal is a Member of the TriSalus Scientific Advisory Board and Investigator for the PERIO-01study. My name is Rich Carvajal. I’ m a medical Oncologist at Columbia University Irving Medical Center where I oversee the melanoma program as well as the experimental therapeutics program. Text on screen: What Are the Challenges in Trying to Find a Cure for Liver Cancer? Well cancers that go to the liver are extremely challenging to treat. You know, if we look at any cancer – whether it’ s pancreatic cancer, colon cancer, uveal melanoma, skin melanoma – if it goes to the liver, it is invariably harder to treat. Overall survival that we see in these patients is inferior to patients who don’ t have liver disease. Text on screen: How Does TriSalus Try...",
"TriSalus Corporate Twitter Post Listen to Dr. Richard Carvajal, member of our scientific advisory board and investigator on the PERIO™-01 #clinicaltrial, discuss challenges of treating #livercancer, our investigational platform, and early findings from the PERIO™ trials below👇 https://youtu.be/zvgCMqUcZ-M TriSalus Corporate LinkedIn Post Listen to Dr. @Richard Carvajal, member of our scientific advisory board and investigator on the PERIO™-01 #clinicaltrial, discuss the challenges of treating #livercancer, what makes our investigational platform unique, and early findings from the ongoing PERIO TM clinical trials below 👇 https://youtu.be/zvgCMqUcZ-M" |
|
| 12/16/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 12/15/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 12/07/2022 |
8-K
| Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits Interactive Data |
| 12/02/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"AMENDMENT NO. 1 TO PROMISSORY NOTE Dated as of December [•], 2022 Principal Amount: Up to $[●] New York, New York MedTech Acquisition Corporation, a Delaware corporation , hereby amends its promissory note, dated as of [●] , effective as of the date hereof, to delete and replace Section 1 of the Original Note in its entirety with the following: 1. Principal . The Payee shall be obligated to lend to the Maker amounts up to the Maximum Principal Amount. The principal balance of this Note, as reflected on Schedule A hereto , shall be repayable on the date on which the Maker consummates a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses . No amount shall be due under this Note if such Initi..." |
|
| 11/21/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 05/26/2022 |
8-K
| Quarterly results |
| 03/10/2022 |
8-K
| Quarterly results |
| 03/07/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/23/2022 |
8-K
| Quarterly results |
| 01/28/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 12/30/2021 |
8-K
| Quarterly results |
| 12/09/2021 |
8-K
| Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review  ... |
| 08/13/2021 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits|
Docs:
|
"Business Combination Agreement, by among MedTech Acquisition Corp., Memic Innovative Surgery Ltd., and Maestro Merger Sub, Inc",
"Sponsor Letter Agreement",
"Form of Memic Voting Agreement",
"Confidentiality and Lock-Up Agreement, by and among Memic Innovative Surgery Ltd., MedTech Acquisition Corp., MedTech Acquisition Sponsor LLC and the other parties named therein",
"Form of Registration Rights Agreement",
"Form of PIPE Subscription Agreement",
"Investor Contact:",
"Investor Presentation",
"Script for August 13, 2021 Investor Call" |
|
| 06/03/2021 |
8-K
| Quarterly results |
| 06/02/2021 |
8-K
| Quarterly results |
| 05/03/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/22/2021 |
8-K
| Quarterly results |
| 02/05/2021 |
8-K
| Quarterly results |
| 12/30/2020 |
8-K
| Other Events, Financial Statements and Exhibits |
|
|